TT 235
Latest Information Update: 07 Mar 2008
Price :
$50 *
At a glance
- Originator Northwestern University Feinberg School of Medicine; University of Illinois
- Developer Mitsubishi Pharma Corporation; Northwestern University Feinberg School of Medicine; University of Illinois
- Class
- Mechanism of Action Oxytocin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Preterm labour
Most Recent Events
- 26 Sep 2006 No development reported - Phase-I for Preterm labour in Japan (unspecified route)
- 26 Sep 2006 No development reported - Phase-I for Preterm labour in USA (unspecified route)
- 26 Jun 2002 This compound is still in active development